Defence Therapeutics Announces Convertible Debenture Conversion

Core Insights - Defence Therapeutics Inc. has announced the conversion of its 8% convertible debentures into common shares, totaling 2,607,600 shares upon maturity on November 16, 2025 [1][2] Group 1: Financial Details - The principal amount of $1,476,000 was converted into 2,460,000 shares at a conversion price of $0.60 per share [2] - An aggregate amount of $118,080 of accrued interests was converted into 147,600 shares at $0.80 per share, bringing the total conversion value to $1,594,080 [2] Group 2: Company Overview - Defence Therapeutics is a publicly-traded biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology [3] - The ACCUM® technology allows for precision delivery of ADCs to target cells, enhancing efficacy and potency against cancer [3]